



Dyslipidemia in Primary Care:

Addressing Barriers to Optimal Lipid Management

YOU ARE INVITED TO JOIN US...

for an interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice.

Join us for a group learning session

Date:

Location:

Program Start Time:

Program End Time:

Speaker(s):

Moderator:

Registration / Meal Comments:

RSVP:

AGENDA

Dyslipidemia in Primary Care:

Addressing Barriers to Optimal Lipid Management

■ The following topics will be covered during this program:

- ✓ Centrality of LDL Cholesterol
- ✓ Guidelines vs. Real World
- ✓ Limitations of Current Therapies
- ✓ Non-Statin Strategies to Reduce LDL-C
- ✓ PCSK9 Inhibitors: News and Pearls
- ✓ Improving Outcomes in Our Patients

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Recognize the centrality of LDL-C and its cumulative exposure to increased risk of ASCVD events
- Evaluate the limitations of current lipid lowering agents and assess recommendations for lipid lowering agents beyond, or in addition to, statin therapy for high risk patients
- Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk
- Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events
- Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

This one-credit-per-hour Group Learning program has been certified by the
College of Family Physicians of Canada and the
for up to Mainpro+ credits.

This program has received an educational grant and in-kind support from Amgen Canada

